Malin investee company Novan announces positive Phase 2 trial data for its antiviral candidate SB206 for the treatment of molluscum contagiosum

Dublin-Ireland, 15 November 2018: Malin Corporation plc’s (ISE:MLC) investee company, Novan Inc. (“Novan”) (NASDAQ:NOVN), announced positive preliminary top line results for three full cohorts of four from a Phase 2 clinical trial for its topical antiviral candidate SB206 for the treatment of molluscum contagiosum, a contagious skin infection caused by the molluscipox virus.

Read the full press release